AbCellera Biologics
ABCL · NASDAQ · Healthcare
$12.63
$0.10 (-0.79%) today
Market Cap
$4.09B
24h Volume
$68.4M
P/E Ratio
0.0
52w High
$12.73
52w Low
$2.78
Est. AI Revenue
75%
7-Day Sparkline (Static)
Company facts
Performance
About AbCellera Biologics
AbCellera Biologics hunts antibodies with AI. The company screens millions of immune cells from natural immune responses, then applies machine learning to identify antibody candidates for drug development. It earns revenue through partnerships with pharmaceutical companies, collecting research fees, milestone payments, and royalties on drugs discovered with its platform.
Its technology stack pairs microfluidic single cell screening with computation, including the Trianni humanized mouse for generating human antibodies and the OrthoMab platform for building bispecific antibodies. Its partnership record includes work with Eli Lilly on antibody therapeutics, and it is advancing internal programs toward the clinic.
Founded in 2012 out of research at the University of British Columbia, AbCellera is headquartered in Vancouver, Canada, employs about 560 people, and trades on the NASDAQ.
AbCellera Biologics in the AI buildout
AbCellera works in the AI Healthcare layer as a discovery engine rather than a drug seller. Its value proposition is speed and hit quality: machine learning over massive single cell datasets finds antibody candidates that conventional screening misses. Revenue arrives through partner fees, milestones, and royalties, which makes results lumpy and pushes the payoff years out. The AI thesis is that a data advantage in antibody discovery compounds over time, similar to platform peers in computational drug discovery.
ABCL is tracked in AI Healthcare, rated Core on the AI Exposure leaderboard.
By the numbers
52-week range
ABCL trades at $12.63, 99% of the way up its 52-week range of $2.78 to $12.73.
Market cap
Market capitalization is $4.09B, with an AI Exposure Score of 78 out of 100.
Next earnings
AbCellera Biologics is next expected to report earnings on November 5, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does AbCellera Biologics do?
AbCellera Biologics discovers antibody drugs for partners. It screens natural immune responses at single cell scale, applies machine learning to select the best antibody candidates, and hands them to pharmaceutical partners for development in exchange for fees, milestones, and royalties.
How is AbCellera Biologics exposed to AI?
Its discovery platform's edge comes from machine learning over massive screening datasets, making AI core to the product it sells partners. Supercycle rates it Core with an AI Exposure Score of 78 out of 100, comparable to other AI driven drug discovery platforms.
Is ABCL a pure play AI stock?
Not quite. The platform is AI driven, but outcomes also depend on wet lab biology, clinical trial results, and partner decisions, and revenue is milestone and royalty based. Supercycle places it in the Core tier rather than Pure Play.
What is AbCellera known for?
Its highest profile work came with Eli Lilly on antibody therapeutics, including a widely used COVID-19 antibody discovered in record time. That program demonstrated the platform's speed and validated its approach of pairing single cell screening with machine learning.
Who leads AbCellera Biologics?
Co-founder Carl Hansen serves as chief executive. A former University of British Columbia professor, he built the company around microfluidic single cell analysis technology developed in his academic lab and has led it since its founding in 2012.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.